What's really exciting is that they are not reinventing the wheel! Oxyntomodulin is already tried tested proven and works. Problem is you need twice/day injections. CTP opko patened tech extends half life and makes Oxyn. once a week injection with same results! That's why this is Doc. Frost's fav molecule. And his pet project. 16 - 100 bil $ peak sales.
Doc is building something truly mind blowing.
Opko is a behemoth in the making.
Even $19 and change in three years will have been a steal.
At $10 and change buy as much as you can.
Downside at worst $3-4.
Upside $$30-50 easily in 10 years.
Picked up more at .77 today to add to my position.
Is this the low?
I think not. But early stage bios like Cocp give you years to build positions.
If you believe in the story. Set low ball limit orders and be patient.
Use days like today to be opknistic.
Effective vaccines for hep c, norovirus, influenza and more could be an absolute home run.
Understood, but the reward for your patience could be huge,
Remember Pharmassat went for $11 bill for basically one drug sovavadi.
Hep C is a very large market and unfortunately growing. CC1845 is looking good for norovirus as well. "Two shots on goal", big pharma asleep, patents filed.
Is this strategic investment a possible knock it out of the park, home run? Ala P.F. Previous comments. Only time will tell. That time? 5-7 years?
Success belongs to those who see opkotunity, before that opkotunity becomes obvious.
In the s3 they state the$15 mil should last them at least 12 months at present burn rate.
Some of my questions are when, who, frequency and how(type of offering)?
The more pressing question is how this dilution will effect the share price over the short and long term?
The money is needed to accomplish their business plan.
Last round of funding was bought by insiders.
COCP is now 75% owned by insiders.
Market cap. 700 mil'ish
This is a marathon not a sprint.
I think we get a pull back here with dilution and general market malaise.
If you believe in this story use this time to be Opkonistic and start and or build your position.
CC-1845 Is Cocrystal's crown jewel!
Compelling potential drug properties,
-Novel pan prodrug: delivers three active
nucleoside 5’-triphosphates – One IND needed.
-2 of the 3 active metabolites of
showed comparable potency to sofosbuvir.
-Equivalent NTP potency compared to sofosbuvir in human hepatocytes.
While Gilead had its own hep-C program, it bought Pharmasset, (Dr. S's company) including what we know call Sovaldi, for $11 billion in 2011. Not only did Sovaldi record sales of $2.3 billion in Q1, but an even more effective combination of Sovaldi with ledipasvir is highly likely to be on the market before the end of the year. [Total Q1 revenue was $5.0 billion.]